Evidence map›Paper›PMID 40618046›Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

Targeting PFKFB3 to restore glucose metabolism in acute pancreatitis via nanovesicle delivery.

Hai Jiang, Zhipeng Xu, Qi Song, Junjie Tao, Jia Liu, Qiang Wang, Huaisheng Zhang, Heng Zhu, Qiliang Li, Lei Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hai JiangDepartment of Emergency Surgery, the First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233000, Anhui Province, China.
Zhipeng XuDepartment of Emergency Surgery, the First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233000, Anhui Province, China.
Qi SongDepartment of Emergency Surgery, the First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233000, Anhui Province, China.
Junjie TaoDepartment of Emergency Surgery, the First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233000, Anhui Province, China.
Jia LiuDepartment of Emergency Surgery, the First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233000, Anhui Province, China.
Qiang WangDepartment of Emergency Surgery, the First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233000, Anhui Province, China.
Huaisheng ZhangDepartment of Emergency Surgery, the First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233000, Anhui Province, China.
Heng ZhuDepartment of Emergency Surgery, the First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233000, Anhui Province, China.
Qiliang LiDepartment of Emergency Surgery, the First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233000, Anhui Province, China.
Lei LiDepartment of Emergency Surgery, the First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233000, Anhui Province, China. lileibyfy@163.com.

Funding

Anhui Provincial Financial Support Project / General Project No. AHWJ2023A20220Provincial Financial Support Program/General Program AHWJ2023A20220Scientific Research Project of Higher Education Institutions in Anhui Province No. 2024AH051287
6 · The paper itself

Abstract

backgroundAcute pancreatitis (AP) is a severe inflammatory disease frequently accompanied by disturbances in glucose metabolism, which further complicate the disease prognosis. This study aims to explore the role of PFKFB3, a key glycolytic enzyme, in regulating glucose metabolism in AP and assess the potential of PFKFB3 inhibition via nanovesicle delivery to mitigate metabolic dysfunction.

methodsTranscriptomic data from Gene Expression Omnibus (GEO), including single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing, were analyzed to investigate the molecular mechanisms involved in glucose metabolism dysregulation in AP. The therapeutic effects of PFKFB3 inhibition via nanovesicle-based delivery were evaluated using both in vivo and in vitro AP models.

resultsPFKFB3 inhibition significantly restored normal glycolytic function and improved glucose metabolism in AP models. Moreover, nanovesicle-mediated delivery also alleviated both inflammation and metabolic disturbances, highlighting its promise as a therapeutic strategy for managing glucose dysfunction in AP.

conclusionOur findings identify PFKFB3 as a critical therapeutic target for treating glucose metabolism disorders in acute pancreatitis. Nanovesicle-based PFKFB3 inhibition may serve as an innovative approach to address metabolic complications associated with AP, offering a new direction for therapeutic interventions in inflammatory diseases.

Indexed as

GlucosePancreatitisPhosphofructokinase-2AnimalsDisease Models, AnimalGlycolysisHumansMaleMiceGlucosePFKFB3 protein, humanPFKFB3 protein, mousePhosphofructokinase-2Acute pancreatitisGlucose metabolism disorderMachine learningNanovesiclesPFKFB3 inhibitorSingle-cell RNA sequencing

Identifiers

PMID40618046
PMCPMC12229013

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.